Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome

Chinese Medical Journal

Volumn 121, Issue 23, 2008, Pages 2434-2439

  Tong, Xiao Mei ^a   Zhang, Song Ying ^a   Song, Tao ^a   Xu, Wei Hai ^a   Lin, Xiao Na ^a   Shu, Jing ^a   Liu, Liu ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Gonadotropin releasing hormone agonist; Gonadotropin releasing hormone antagonist; Ovarian hyperstimulation syndrome; Vascular endothelial growth factor

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; EVANS BLUE; MESSENGER RNA; TRIPTORELIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 120; VASCULOTROPIN 164; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; DRUG DERIVATIVE; GONADORELIN; LHRH, N ACETYL (4 CHLOROPHENYLALANYL)(1) (4 CHLOROPHENYLALANYL)(2) TRYPTOPHYL(3) ARGINYL(6) ALANINE(10); LHRH, N-ACETYL-(4-CHLOROPHENYLALANYL)(1)-(4-CHLOROPHENYLALANYL)(2)-TRYPTOPHYL(3)-ARGINYL(6)-ALANINE(10)-; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; ESTRADIOL BLOOD LEVEL; FEMALE; GENE EXPRESSION; LIVER; LUNG PARENCHYMA; NONHUMAN; OVARY HYPERSTIMULATION; PERITONEUM; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WISTAR RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM;

ANIMALS; BLOTTING, WESTERN; CHORIONIC GONADOTROPIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GONADOTROPIN-RELEASING HORMONE; OVARIAN HYPERSTIMULATION SYNDROME; RATS; RATS, WISTAR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63149187387     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200812010-00014     Document Type: Article

References (27)

1. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002; 8: 559-577.
2. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003; 9: 275-289.
3. Jakimiuk AJ, Grzybowski W, Zakrzewski J, Lewandowski P, Koziol K. The ovarian hyperstimulation syndrome - diagnostic criteria, management procedures. Ginekol Pol 2006; 77: 885-892.
4. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol 2004; 115 (Suppl 1): s44-s56.
5. Dal Prato L, Borini A. Use of antagonist in ovarian stimulation protocols. Reprod Biomed Online 2005; 10: 330-338.
6. Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005; 20: 2421-2425.
7. Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmuller-Winzen H, Schuler A, et al. Significant reduction of the occurrence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 2000; 264: 29-32.
8. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a cochrane review. Hum Reprod 2002; 17: 874-885.
9. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007; 15: 408-412.
10. Chen XY, Li JS, Liang QP, He DZ, Zhao J. Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J 2008; 121: 881-886.
11. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344: 235-236.
12. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, et al. Human chorionic gonadotrophin-dependent expression of vascular entothelial growth factor/vascular permeability factor in human granulose cells:importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 80: 1967-1971.
13. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 1999; 71: 287-293.
14. Ujioka T, Matsuura K, Kawano T, Okamura H. Role of progesterone in capillary permeability in hyperstimulated rats. Hum Reprod 1997; 12: 1629-1634.
15. Kitajima Y, Endo T, Manase K, Nishikawa A, Shibuya M, Kudo R. Gonadotrophin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril 2004; 81 (Suppl 1): s842-s849.
16. Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 2001; 280: H434-H440.
17. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998; 102: 1978-1985.
18. Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002; 143: 4339-4348.
19. Christenson LK, Stouffer RL. Follicle-stimulating hormone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by macaque granulosa cells from pre- and periovulatory follicles. J Clin Endocrinol Metab 1997; 82: 2135-2142.
20. Neulen J, Raczek S, Pogorzelski M, Grunwald K, Yeo TK, Dvorak HF, et al. Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulose cells is human chorionic gonadotrophin dependent. Mol Hum Reprod 1998; 4: 203-206.
21. Manau D, Fábregues F, Peñarrubia J, Creus M, Carmona F, Casals G, et al. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF. Hum Reprod 2007; 22: 669-675.
22. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006; 12: 333-340.
23. Kitajima Y, Endo T, Nagasawa K, Manase K, Honnma H, Baba T, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006; 147: 694-699.
24. Dan P, Cheung JC, Scriven DR, Moore ED. Epitope-dependent localization of estrogen receptor-alpha, but not-beta, in en face arterial endothelium. Am J Physiol Heart Circ Physiol 2003; 284: H1295-H1306.
25. Cho MM, Ziats NP, Pal D, Utian WH, Gorodeski GI. Estrogen modulates paracellular permeability of human endothelial cells by eNOS- and iNOS-related mechanisms. Am J Physiol 1999; 276: C337-C349.
26. Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD. Cloning, sequencing, and expression of human gonadotrophin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 1992; 189: 289-295.
27. Kaiser UB, Zhao D, Cardona GR, Chin WW. Isolation and characterization of cDNAs encoding the rat pituitary gonadotropin-releasing hormone receptor. Biochem Biophys Res Commun 1992; 189: 1645-1652.